ISRCTN16457874进行中（未招募）1 期
A phase 1 study of JNJ-80038114, a T-Cell redirecting agent targeting prostate specific membrane antigen (PSMA), for advanced stage prostate cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. 18 years and older
- •2. Metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate as defined by Prostate Cancer Working Group 3 (PCWG3)
- •3. Measurable or evaluable disease
- •4. At least 1 prior treatment for mCRPC
- •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •6. Adequate organ functions as defined by certain laboratory values
- •7. Must sign an informed consent form (ICF)
- •8. Participants must agree to use a highly effective form of birth control as guided by the study doctor
排除标准
- •1. Concurrent anticancer therapy
- •2. Severe or long-lasting side effects related to prior anticancer therapy
- •3. Known allergies to JNJ-80038114 or its excipients
- •4. Brain metastasis or known seizure history
- •5. Significant infections or lung, heart or other medical conditions
研究者
相似试验
招募中
1 期
A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative NeoplasmsCALR-mutated Myeloproliferative NeoplasmsCTIS2023-505584-36-00Janssen - Cilag International95
招募中
不适用
A Phase 1 Study of JNJ-78278343, a T Cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancerprostate carcinoma10038597Prostate cancerNL-OMON53995Janssen-Cilag25
已完成
1 期
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate CancerProstatic NeoplasmsNCT05441501Janssen Research & Development, LLC39
已完成
1 期
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid TumorsAdvanced Stage Solid TumorsNCT06255665Janssen Research & Development, LLC35
进行中（未招募）
1 期
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate CancerProstatic NeoplasmsNCT04898634Janssen Research & Development, LLC216